Biosketch

Nicolas Venteclef has been leading a research team at the INEM since 2021. Before that, he was team leader in Cordeliers Research Centre.  During his scientific path, he has developed strong expertise in the regulation of gene expression, epigenomics, nuclear receptor signalling, metabolic and inflammatory disease pathways and diabetes.

Nicolas Venteclef completed his PhD at the GloxoSmithKline Laboratory in France (GSK Pharma) with a dissertation about “inflammatory function of a transcription factor named Liver Receptor Homolog-1 (LRH-1) in liver”. He did his postdoc at the Karolinska Institutet where he identified the anti-inflammatory action of a transcriptional regulator named GPS2 (G-Protein Pathway suppressor 2).  Since this major discovery, he has particular interest in decoding and understanding how the transcriptomic and epigenomic mechanisms controls metabolic and inflammatory pathways in the context of type 2 diabetes and its related complications (fatty liver disease and atherosclerosis) in mice and humans.

His team’s project centers on advancing our comprehension of the interplay between the immune and metabolic systems, considering environmental influences. Our goal is to examine the implications of this interplay in human health and disease, with a particular emphasis on diabetes.